Kidney Disease

It has been almost 3 years since the beginning of the COVID-19 pandemic. Much has changed since then, yet still this virus and its variants pose a threat.

PHILADELPHIA — Half of patients with systemic lupus erythematosus and new-onset, low-grade proteinuria progress to clinical proteinuria within 2 years, according to results of a study presented at ACR Convergence 2022.

Fifty years after Congress enacted the End-Stage Renal Disease Program in 1972, the American Society of Nephrology celebrates the milestone in American kidney health.

ORLANDO — In this video from ASN Kidney Week, Samir V. Parikh, MD, discusses the results of the AURORA 2 study.

ORLANDO — Isuzinaxib, a pan-NOX inhibitor modulating oxidative stress by Aptabio significantly reduced urine albumin-to-creatinine ratio in patients with type 2 diabetes and chronic kidney disease, according to data at ASN Kidney Week.

ORLANDO — In this video from ASN Kidney Week, Mike Spigler, shared the results of a survey connected to the Unknown Causes of Kidney Disease Project regarding genetic testing for chronic kidney disease.

ORLANDO — SGLT2 inhibitors reduce the risk and progression of chronic kidney disease and AKI regardless of diabetes status, according to data presented at ASN Kidney Week.

ORLANDO — Patients with chronic kidney disease did not see a change in kidney function when clinicians continued a course of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, according to a study presented here.

Research published in The Journal of Clinical Endocrinology & Metabolism highlighted the need for better evidence on long-term health consequences of gestational diabetes.

Among older adults with advanced chronic kidney disease, those who knew the range of kidney treatment options or attended an educational class about their options were more likely to engage in shared decision-making, according to a study.